Nika BioTechnology Inc
Nika Pharmaceuticals, Inc., a pharmaceutical company, develops drugs for the treatment of HIV/AIDS, hepatitis B and C, rheumatoid arthritis, cancer, diabetes, and various other diseases. It offers dietary supplements and antiviral drugs, as well as thymus nuclear glycoprotein for the treatment of HIV. The company was formerly known as Centennial Growth Equities Inc. and changed its name to Nika P… Read more
Nika BioTechnology Inc (NIKA) - Total Liabilities
Latest total liabilities as of September 2025: $284.16K USD
Based on the latest financial reports, Nika BioTechnology Inc (NIKA) has total liabilities worth $284.16K USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nika BioTechnology Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how Nika BioTechnology Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Nika BioTechnology Inc Competitors by Total Liabilities
The table below lists competitors of Nika BioTechnology Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Blue Water Acquisition Corp. III Unit.
NASDAQ:BLUWU
|
USA | $9.15 Million |
|
Keros Therapeutics Inc
NASDAQ:KROS
|
USA | $39.20 Million |
|
TFF Group
PINK:FRFTF
|
USA | $464.31 Million |
|
Qingdao Greensum Ecology Co. Ltd.
SHE:300948
|
China | CN¥793.80 Million |
|
Zilltek Technology Corp
TWO:6679
|
Taiwan | NT$735.95 Million |
|
Suzhou W Deane New Power Elec
SHG:603312
|
China | CN¥1.20 Billion |
|
Miracll Chemicals Co Ltd
SHE:300848
|
China | CN¥2.74 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Nika BioTechnology Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 12.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nika BioTechnology Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nika BioTechnology Inc (2016–2024)
The table below shows the annual total liabilities of Nika BioTechnology Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $239.16K | +135.06% |
| 2023-12-31 | $101.75K | +459.65% |
| 2022-12-31 | $18.18K | -24.31% |
| 2021-12-31 | $24.02K | +128.35% |
| 2020-12-31 | $10.52K | -94.23% |
| 2019-12-31 | $182.30K | +3.76% |
| 2018-12-31 | $175.69K | +10.25% |
| 2017-12-31 | $159.36K | +47.56% |
| 2016-12-31 | $108.00K | -- |